We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-0.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.89B
AUM Growth
-$643M
Cap. Flow
-$392M
Cap. Flow %
-5.69%
Top 10 Hldgs %
36.47%
Holding
178
New
7
Increased
49
Reduced
68
Closed
19

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$49.8M
2
ALGN icon
Align Technology
ALGN
+$27.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.9M
4
VEEV icon
Veeva Systems
VEEV
+$13.1M
5
LEGN icon
Legend Biotech
LEGN
+$7.46M

Top Sells

Rank Stock Value
1
MYOV
Myovant Sciences Ltd.
MYOV
+$159M
2
CI icon
Cigna
CI
+$30.6M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$27.6M
4
ELV icon
Elevance Health
ELV
+$26.9M
5
DXCM icon
DexCom
DXCM
+$26.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.07%
2 Industrials 0.84%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HSIC icon
151
Henry Schein
HSIC
$9.74B
$85K ﹤0.01%
+1,043
New +$85K
TSM icon
152
TSMC
TSM
$2.09T
$71.6K ﹤0.01%
770
– –
JMIA
153
Jumia Technologies
JMIA
$726M
$59.2K ﹤0.01%
18,000
– –
ASR icon
154
Grupo Aeroportuario del Sureste
ASR
$8.03B
$41.4K ﹤0.01%
135
– –
KZR
155
DELISTED
Kezar Life Sciences
KZR
$31.3K ﹤0.01%
1,000
-302,100
-100% -$17.5M
EQIX icon
156
Equinix
EQIX
$107B
$28.8K ﹤0.01%
40
– –
EVTC icon
157
Evertec
EVTC
$1.83B
$24.9K ﹤0.01%
739
– –
UMC icon
158
United Microelectronic
UMC
$48.9B
$23.6K ﹤0.01%
2,698
– –
INFY icon
159
Infosys
INFY
$45B
$19.7K ﹤0.01%
1,130
– –
A icon
160
Agilent Technologies
A
$39.1B
– –
-7,978
Closed -$1.19M
ACHC icon
161
Acadia Healthcare
ACHC
$3.17B
– –
-1,287
Closed -$106K
ADPT icon
162
Adaptive Biotechnologies
ADPT
$3.56B
– –
-2,960,131
Closed -$22.6M
AUPH icon
163
Aurinia Pharmaceuticals
AUPH
$1.97B
– –
-1,290,278
Closed -$5.57M
AVTR icon
164
Avantor
AVTR
$7.81B
– –
-471,621
Closed -$9.95M
DLB icon
165
Dolby
DLB
$4.72B
– –
-1,600
Closed -$113K
DSGN icon
166
Design Therapeutics
DSGN
$736M
– –
-34,881
Closed -$358K
MELI icon
167
Mercado Libre
MELI
$91.3B
– –
-170
Closed -$144K
MKTX icon
168
MarketAxess Holdings
MKTX
$4.15B
– –
-662
Closed -$185K
NKTR icon
169
Nektar Therapeutics
NKTR
$2.39B
– –
-987
Closed -$33.4K
NVCR icon
170
NovoCure
NVCR
$2.04B
– –
-9,000
Closed -$660K
RCUS icon
171
Arcus Biosciences
RCUS
$3.57B
– –
-65,864
Closed -$1.36M
TFX icon
172
Teleflex
TFX
$5.85B
– –
-25,066
Closed -$6.26M
UTHR icon
173
United Therapeutics
UTHR
$26.3B
– –
-212
Closed -$59K
QTTB icon
174
Q32 Bio
QTTB
$450M
– –
-90,140
Closed -$2.04M
CELL
175
DELISTED
PhenomeX Inc. Common Stock
CELL
– –
-385,014
Closed -$1.03M
4 5 6
7
8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2023 Portfolio in Review

As of Q1 2023, Bellevue Group held 178 positions worth $6.89B, down 8.5% from $7.53B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group withdrew a net $392M in Q1 2023, closing 19 positions and reducing 68 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $159M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Verona Pharma worth $5.27M.

  • Bellevue Group's largest Q1 2023 buy was Verona Pharma: 262,683 shares worth $5.27M.
  • Bellevue Group added most to Medtronic in Q1 2023, an estimated $49.8M increase.
  • Bellevue Group's biggest Q1 2023 reduction was Cigna, cutting an estimated $30.6M.
  • Bellevue Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $159M.
  • Bellevue Group's ten largest holdings make up 36% of its $6.89B portfolio in Q1 2023.
  • Bellevue Group opened 7 new positions and closed 19 in Q1 2023.
  • Bellevue Group's portfolio value fell 8.5% quarter-over-quarter to $6.89B.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.